|
PTPN9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.23519999783994E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.45649999628139E-08 |
| Normal-vs-Stage2 |
3.97180000000219E-05 |
| Normal-vs-Stage3 |
1.13150000480289E-09 |
| Normal-vs-Stage4 |
2.30119999722334E-08 |
| Stage1-vs-Stage2 |
5.847800E-01 |
| Stage1-vs-Stage3 |
5.133800E-02 |
| Stage1-vs-Stage4 |
1.678210E-01 |
| Stage2-vs-Stage3 |
7.322300E-02 |
| Stage2-vs-Stage4 |
1.623400E-01 |
| Stage3-vs-Stage4 |
9.515600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.96379995493135E-09 |
| Normal-vs-AfricanAmerican |
1.915760E-02 |
| Normal-vs-Asian |
4.11320000281989E-08 |
| Caucasian-vs-AfricanAmerican |
5.554200E-02 |
| Caucasian-vs-Asian |
8.444000E-01 |
| AfricanAmerican-vs-Asian |
6.166400E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.67490000149806E-08 |
| Normal-vs-Female |
1.56430000064489E-08 |
| Male-vs-Female |
8.614400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.1511999948618E-08 |
| Normal-vs-Age(41-60Yrs) |
7.99039999721529E-08 |
| Normal-vs-Age(61-80Yrs) |
2.07460004730819E-09 |
| Normal-vs-Age(81-100Yrs) |
1.77837999999486E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.282200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.639810E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.910400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.184790E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.151400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.341400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.992730E-04 |
| Classical-VS-Follicular |
1.078820E-01 |
| Classical-VS-Other |
7.456600E-01 |
| Classical-VS-Normal |
3.55270000085284E-08 |
| Tall-VS-Follicular |
5.6268000000026E-05 |
| Tall-VS-Other |
2.698600E-01 |
| Tall-VS-Normal |
1.83130177688895E-11 |
| Follicular-VS-Other |
8.108200E-01 |
| Follicular-VS-Normal |
1.60399999999949E-05 |
| Other-VS-Normal |
4.024000E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.08699999504347E-08 |
| Normal-vs-N1 |
7.45510000399463E-08 |
| N0-vs-N1 |
2.198000E-01 |
|
|
